Cidara Therapeutics (NASDAQ:CDTX) is a clinical‐stage biotechnology company headquartered in San Diego, California, focused on the discovery, development and commercialization of novel therapies for life‐threatening fungal and viral infections. Founded in 2015, the company leverages its proprietary platforms to develop long‐acting therapeutics designed to address significant unmet medical needs. Cidara’s research and development efforts are centered on creating treatments with improved safety, dosing convenience and broad-spectrum activity.
The company’s lead antifungal candidate, rezafungin (CD101), is a next‐generation echinocandin designed for once‐weekly intravenous or topical administration. Rezafungin is being evaluated for the prevention and treatment of invasive candidiasis, candidemia and other serious fungal infections, with the aim of reducing hospital stays and improving patient outcomes. Cidara has established strategic collaborations and licensing partnerships to support global development and commercialization of rezafungin.
In parallel, Cidara is advancing its Cloudbreak® mRNA platform to generate prophylactic and therapeutic antibodies against viral pathogens, including influenza and coronaviruses. This platform uses modified mRNA to program the human body to produce protective antibodies in vivo, offering potential for rapid response to emerging viral threats. Early‐stage programs include long‐acting antibody products for the prevention of COVID-19 and seasonal flu, positioning Cidara at the forefront of mRNA‐based immunotherapies.
Cidara’s leadership team combines expertise in infectious disease, drug development and regulatory affairs. Under the direction of President and CEO Jeffrey Cleland, Ph.D., the company has advanced its pipeline through multiple clinical milestones and regulatory interactions. Cidara operates primarily in the United States, with partnerships and development activities extending into Europe and Asia. The company continues to expand its scientific collaborations with academic institutions and biotechnology partners to accelerate the delivery of life‐saving therapies.
